GGrantIndex
← Search

Cancer Center Support Grant

$100,117P30FY2012CANIH

Univ Of Med/Dent Nj-R W Johnson Med Sch, Piscataway NJ

Investigators

Linked publications, trials & patents

Trial NCT05639972Trial NCT05483491Trial NCT05296421Trial NCT04929015Trial NCT04920344Trial NCT04871516Trial NCT04751747Trial NCT04445844Trial NCT04294264Trial NCT04285268Trial NCT04253483Trial NCT04211259Trial NCT04179227Trial NCT04163952Trial NCT04146038Trial NCT04081688Trial NCT03902379Trial NCT03725449Trial NCT03677739Trial NCT03456843Trial NCT03448224Trial NCT03441321Trial NCT03428802Trial NCT03272633Trial NCT03257163Trial NCT03233555Trial NCT03229278Trial NCT03228147Trial NCT03112668Trial NCT03108911Trial NCT03102060Trial NCT03061175Trial NCT03028948Trial NCT02949284Trial NCT02885649Trial NCT02748564Trial NCT02699996Trial NCT02688517Trial NCT02688192Trial NCT02621398Trial NCT02526511Trial NCT02526498Trial NCT02458716Trial NCT02421575Trial NCT02420652Trial NCT02324621Trial NCT02324608Trial NCT02315196Trial NCT02295540Trial NCT02294617Trial NCT02250781Trial NCT02203604Trial NCT02203578Trial NCT02177838Trial NCT02144701Trial NCT02144675Trial NCT02105116Trial NCT01828476Trial NCT01694589Trial NCT01652014Trial NCT01649947Trial NCT01480154Trial NCT01417286Trial NCT01407562Trial NCT01303341Trial NCT01251172Trial NCT01032590Trial NCT01018836Trial NCT01009931Trial NCT01006369Trial NCT00996359Trial NCT00991315Trial NCT00966667Trial NCT00962845Trial NCT00946283Trial NCT00943709Trial NCT00939380Trial NCT00934895Trial NCT00909909Trial NCT00905918Trial NCT00900120Trial NCT00899808Trial NCT00899639Trial NCT00895115Trial NCT00891969Trial NCT00878657Trial NCT00866840Trial NCT00853125Trial NCT00813423Trial NCT00786682Trial NCT00770419Trial NCT00770055Trial NCT00769652Trial NCT00765765Trial NCT00749437Trial NCT00740805Trial NCT00728845Trial NCT00726596Trial NCT00669734Trial NCT00667901

Abstract

PROJECT SUMMARY (See instructions): The Cancer Institute of New Jersey (CINJ) prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated States in our Nation. As a matrix and consortium cancer center that has been continuously funded by the NCI CCSG mechanism since 1997, CINJ conducts state of the art research, patient care, and outreach/education. CINJ is currently comprised of 161 members from a total of 32 academic departments who hold over $92.9 million total peer-reviewed support, $61.1 million annual direct support, $28.9 million total NCI support and $18.7 million annual direct NCI support (a 20% Increase in NCI support since the time ofthe last submission in 2004). Since the appointment of Dr. Robert S. DiPaola as center director in September, 2008, accrual onto investigator initiated therapeutic clinical trials has more than doubled; 17 new faculty were recruited in multiple areas including Basic Science, Clinical Science, Public Health Science, and Systems Biology/Bioinformatics; the Consortium relationship with Princeton University and Rutgers University was strengthened and formalized; the State's cancer registry and SEER contract was moved to CINJ; and an additional four recruitment searches were launched. CINJ now has six established Research Programs: Cell Death and Survival Signaling; Genomic Instability and Tumor Growth; Cancer Pharmacology and Preclinical Therapeutics; Clinical Investigations; Carcinogenesis and Chemoprevention; and Cancer Prevention and Control. CINJ supports 14 Shared Resources, including: Flow Cytometry and Cell Sorting; Functional Genomics; Transgenic and Knockout Mouse; Pharmacokinetics and Pharmacodynamics; Histopathology and Imaging; Biorepository Service; Bioinformatics; Biometrics; Research Pharmacy; Office of Human Research Services; Centralized Education and Training for Clinical Research Personnel; Small Animal Imaging (developing); Metabolomics (developing) and Epidemiology Services (developing). Overall, CINJ has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has State-wide authority beyond the University matrix, thus establishing an environment to foster and formalize a Vision of Transdisciplinary and Translational Research within and beyond the University matrix. We are requesting CCSG support for Senior leadership, Program Leadership, Planning and Evaluation, Developmental Funds, Administration, Shared Resources, Protocol Review and Monitoring, Protocol Specific Research Support, and Data and Safety Monitoring.

View original record on NIH RePORTER →